Dermatology

Low dose IL-2 for treating moderate to severe alopecia areata. A 52 weeks multicenter prospective placebo-controlled study assessing its impact on T regulatory cells and natural killer populations



To the Editor, the treatment of severe Alopecia areata (AA) remains highly challenging. A breakdown of immune privilege of the hair follicle resulting in the development of an admixed immune of antigen presenting cells (APCs), CD4+ and CD8+ T lymphocytes infiltrate is hypothesized to represent an important driver of AA(Pratt et al., 2017). A deficiency in T regulatory cells (Tregs) might facilitate the occurrence of this immune privilege breakdown. A growing corpus of data in animal models but also from blood and skin in AA patients emphasized the likely key role of Tregs in AA pathomechanisms(Conteduca et al., 2014, Hamed et al., 2019, McElwee et al., 2005, Petukhova et al., 2010, Shin et al., 2013, Tembhre and Sharma, 2013).

Source link

Related posts

Hair Transplant: It’s ‘hair’ to stay!

Newsemia

Sponsorship Statement/Disclaimer

Newsemia

Learn More About Full Body Skin Exams

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World